Overview of Spiralgin

Quick Facts

Property	Description
Active Ingredient	Mefenamic Acid
Form	Capsule or Tablet (Oral)
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose	Relief of pain, inflammation, and fever
Origin	Synthetic

What is Spiralgin and Its Active Ingredient?

Spiralgin is a trade name for a medication whose sole active ingredient is Mefenamic Acid (INN), a synthetic compound classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Mefenamic Acid belongs specifically to the anthranilic acid derivative, or fenamate, group, distinguishing it chemically from common propionic acid NSAIDs. It is administered via the oral route and provided as a single-ingredient product in solid dosage forms, such as a capsule or tablet. This classification is clinically recognized for its systemic action against inflammatory processes, ensuring the active compound is delivered internally for systemic relief.

What is the Purpose of Mefenamic Acid?

The core therapeutic purpose of Mefenamic Acid is to exert analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) activities. Pharmacological studies confirm that this efficacy is due to the drug's mechanism as a potent inhibitor of cyclooxygenase (COX) enzymes. By blocking COX, the drug effectively halts the synthesis of prostaglandins, which are responsible for generating pain and fever signals. The overall function of the medication is to chemically interrupt these biological processes, providing systemic symptomatic relief, for example, in managing general discomfort linked to acute inflammation.

Regulatory References

What side effects are possible with Spiralgin?

Possible Side Effects and Safety Information

Spiralgin (Mefenamic Acid) safety information is primarily defined by the risks associated with its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID). Adverse reactions are formally categorized in regulatory documents based on frequency and affected system-organ class.

Adverse Reaction Scope

The most commonly documented adverse effects in regulatory labels are related to Gastrointestinal Disorders, which include diarrhoea, nausea, vomiting, abdominal pain, and dyspepsia. Diarrhoea is often noted as the most frequent side effect and typically resolves upon discontinuation of therapy. Other documented effects involve the Nervous System (e.g., headache, dizziness) and Blood and Lymphatic System.

Serious Safety Considerations

Regulatory agencies document the potential for rare but serious systemic risks, which are considered a class-effect for NSAIDs. These include the risk of potentially fatal cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal adverse events (including bleeding, ulceration, and perforation). Very rare, severe skin reactions, such as Stevens-Johnson syndrome, are also documented.

Population-Specific Restrictions

Official safety profiles include strict limitations for specific patient groups. The use of Mefenamic Acid is generally contraindicated in patients with severe hepatic, renal, or cardiac failure. Furthermore, it is restricted for use in the third trimester of pregnancy and must be avoided for the treatment of pain immediately following Coronary Artery Bypass Graft (CABG) surgery. The risk of serious gastrointestinal events is also noted to be higher in older adults.

This structure ensures the safety profile is communicated by official classification and restriction, not by clinical advice or therapeutic claims.

Overdose and Emergency Response

Overdose and when to seek help

Spiralgin contains Mefenamic Acid, a Non-Steroidal Anti-Inflammatory Drug (NSAID), which carries specific risks in the event of an overdose. Overdose with Mefenamic Acid is a serious medical event requiring immediate attention.

Overdose Scope and Manifestations

Classification	Detail (Based on Mefenamic Acid)
Documented Overdose Presentations	Symptoms can include kidney failure, severe gastrointestinal problems (including bleeding), rashes, central nervous system effects such as confusion, hallucinations, vertigo, and seizures (convulsions).
Physiological Systems Affected	Primarily the renal (kidney) and gastrointestinal systems, as well as the central nervous system.
Exposure-Related Factors	Overdose risk is associated with exposure to excessive dose levels of the active ingredient, Mefenamic Acid.
Population-Specific Notes	Children and the elderly may be at an increased risk of severe effects.

Emergency Actions and Seeking Medical Help

When immediate medical help is required: Any suspected overdose must be considered a medical emergency. Contact emergency medical services immediately upon recognizing any potential symptoms of overdose or exposure to excessive amounts of Spiralgin.

Required Emergency Actions (as generally described for Mefenamic Acid overdose): Medical management typically involves interventions aimed at reducing drug absorption, such as gastric lavage or the administration of activated charcoal, along with rigorous control of electrolytes and the monitoring of vital functions in a clinical setting. Treatment is primarily supportive.

Therapeutic Uses of Spiralgin

What Spiralgin Treats: Main Uses and Benefits

Spiralgin (Mefenamic Acid) is commonly applied in the symptomatic management of mild to moderate pain and primary dysmenorrhea. This medication is considered relevant for a range of conditions characterized by episodic or fluctuating symptom patterns.

It helps address symptom clusters that may become intense or disruptive, including pelvic cramping, dental pain, musculoskeletal discomfort, and generalized fever. The use is often applied in scenarios requiring short-term assistance, such as managing post-operative discomfort or addressing the flares of rheumatoid arthritis and osteoarthritis.

“The core role of this medication is to provide supportive relief during difficult episodes by easing the overall symptom burden.”

Quick Fact: Relief for Menstrual Cramping and Acute Pain

Spiralgin assists with maintaining functional stability by addressing intense pain associated with the menstrual cycle and short-term inflammatory states.

Regulatory References

NIH DailyMed official prescribing information

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults and adolescents 14 years of age and older.

Populations for whom use is contraindicated:

Patients with known hypersensitivity to the drug or a history of allergic reactions (e.g., asthma, hives) after taking aspirin or other NSAIDs.
Individuals in the setting of Coronary Artery Bypass Graft (CABG) surgery for peri-operative pain.
Patients with active gastrointestinal ulceration, chronic inflammation of the GI tract, or a history of recurrent peptic ulcer or hemorrhage.
Patients with severe renal failure, severe hepatic failure, or severe heart failure (NYHA Class II-IV).

Age-Related Eligibility and Restrictions

Pediatric Threshold: Not recommended for use in children under 14 years of age, as safety and efficacy have not been established.
Geriatric Use: Use requires particular caution in the elderly due to the increased risk of serious gastrointestinal and renal adverse events.

Condition-Specific Eligibility Status

Organ Function: Contraindicated in severe hepatic or renal failure. Use with caution in pre-existing, non-severe hepatic or renal dysfunction.
Cardiovascular Conditions: Contraindicated in severe heart failure. Use with caution in patients with uncontrolled hypertension or pre-existing congestive heart failure.

Pregnancy and Lactation Eligibility Status

Third Trimester: Contraindicated due to the risk of fetal ductus arteriosus closure.
From 20 Weeks Gestation: Avoid use due to the risk of fetal renal dysfunction.
Lactation: Not recommended for use by nursing mothers.

Connection to the overall eligibility profile: Regulatory documents establish a clear framework defining who can and cannot use Spiralgin, primarily based on contraindications related to hypersensitivity, gastrointestinal integrity, and the severity of vital organ function. Eligibility is further structured by specific age minimums and mandated prohibitions during the third trimester of pregnancy, ensuring the patient population is explicitly limited to those for whom risks are officially minimized.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Spiralgin (Mefenamic Acid) is an Nonsteroidal Anti-inflammatory Drug (NSAID) whose interaction profile is defined by pharmacokinetic and pharmacodynamic constraints outlined in official regulatory documents.

Official Interaction Statements

Interaction Type	Interacting Agent	Official Regulatory Statement
Contraindicated	Other Systemic NSAIDs	Co-administration is prohibited due to additive risk of serious gastrointestinal ulcers and bleeding.
Contraindicated	CABG Surgery	Prohibited for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Pharmacodynamic	Oral Anticoagulants	Increases the risk of bleeding and may enhance the anticoagulant response by displacing the agent from protein binding sites.
Exposure Alteration	Magnesium Hydroxide Antacids	Documented to significantly increase the absorption and overall plasma exposure of Mefenamic Acid.
Renal/Clearance	Lithium and Digoxin	Co-administration may increase plasma levels of both substances due to reduced renal clearance.
Efficacy Reduction	Anti-hypertensives	Reduces the effectiveness of Diuretics, ACE Inhibitors, and AIIA/ARBs, potentially leading to deterioration of renal function.

Population and Substance Notes

The interaction profile is especially relevant in elderly patients and those with impaired renal function, where the risk of serious complications, particularly with concomitant use of Diuretics or RAAS inhibitors, is heightened. Ingestion of alcohol is also documented as a factor that increases the risk of serious gastrointestinal complications.

Mechanism of Action

Core Mechanism: Enzyme Inhibition and Pathway Blockade

This domain covers the drug's primary action as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, COX-1 and COX-2. By blocking this enzymatic step, the drug halts the conversion of arachidonic acid into prostaglandins ( PGE2) and related inflammatory mediators. This essential molecular step initiates the cascade that results in altered signaling dynamics within nociceptive and inflammatory pathways.

Dual Action: Central and Peripheral Signaling

Mefenamic Acid engages mechanisms that modulate physiological processes where heightened pathway activity is present in both the periphery and the central nervous system. Peripherally, the drug's mechanism reduces the synthesis of PGE2, a mediator known to sensitize peripheral nociceptors. Centrally, it is applied in systems where targeted pathway adjustment is required, specifically by suppressing PGE2 synthesis in the hypothalamus which results in the modulation of the core body temperature set-point.

Inherent Mechanistic Constraint

The drug's mechanism, being non-selective, also involves the concurrent suppression of COX-1-mediated synthesis of homeostatic prostaglandins. This biological constraint means the mechanism results in the concurrent suppression of both inducible PG synthesis and COX-1-mediated synthesis of homeostatic PGs.

Dosage and Administration Information

Administration Method

Spiralgin is intended for oral use. The tablets should be swallowed whole with a sufficient amount of liquid, such as a glass of water. For patients with sensitive stomachs, it is generally recommended to take the medication during or immediately after meals to minimize potential gastrointestinal discomfort.

Form and Appearance

The medication is typically provided in tablet form. Each tablet is manufactured to ensure a consistent distribution of the active components. If the tablet features a break-mark, it is intended to facilitate breaking the tablet for easier swallowing rather than for dividing the dose into equal halves, unless otherwise specified by a healthcare professional.

Consistency of Use

To achieve the intended effect, the timing of administration should follow a regular schedule. Maintaining consistent intervals between applications helps keep stable levels of the active substance in the bloodstream. If a dose is missed, it is standard practice to resume the schedule with the next planned application rather than increasing the subsequent quantity.

Storage and Handling

Tablets should remain in their original blister packaging until the time of use to protect them from environmental factors such as moisture and light. Store the medication at room temperature in a dry location. Ensure the product is kept in a secure place that is not accessible to children or pets.

Recent Clinical Evidence

Research evidence / Overview of Studies for Spiralgin

This overview summarizes the available research base and clinical studies that have been conducted to evaluate Spiralgin (Mefenamic Acid). The information is sourced from regulatory documents and peer-reviewed scientific literature and focuses on the types of research and the study populations involved.

Evidence for use in Primary Dysmenorrhea (Menstrual Pain/Cramping)

This section will summarize the structure of Randomized Controlled Trials (RCTs) and systematic reviews that have explored Spiralgin in studies focused on menstrual pain, focusing on the specific pain and symptom outcomes measured in these short-term studies.

Research exploring short-term symptom changes was the focus of this indication using RCTs, which are a type of randomized, comparative study. The main study outcomes examined were patient-reported outcomes describing perceived discomfort and the measurement of rescue pain medication use. Findings reported in systematic reviews describe patterns observed in the studies, examining reported discomfort as an outcome. The research provides insight into symptom patterns related to conditions characterized by fluctuating or episodic manifestations.

Evidence for use in Acute Mild to Moderate Pain

This part will detail the research landscape for treating short-term pain, outlining the types of single-dose RCTs used, the acute pain models examined (e.g., post-operative), and the very short-term pain relief metrics recorded in regulatory submissions.

Spiralgin was evaluated in studies focusing on episodes where symptoms become more noticeable. Research examined outcomes related to physical discomfort, monitoring measures over specific, very short time intervals, typically measured over 4 to 6 hours after a single dose. Studies conducted during periods of increased symptom activity reported data concerning Total Pain Relief measurements. The follow-up durations were limited in many of these studies, focusing heavily on single-dose performance.

Long-Term Studies and Follow-Up Duration

The research available for Spiralgin has predominantly focused on short-term or episodic symptom patterns relevant to its labeled uses, such as pain related to menstrual cycles or acute pain events. This means that while research provides insight into short-term changes, there is limited information for long-term outcomes or the consistency of observed patterns over many months or years of intermittent use. The existing studies provide context but not individual predictions.

What is Still Uncertain About Spiralgin Research

This final section will synthesize the major evidence gaps and limitations noted in systematic reviews and regulatory documents. Research findings varied when comparing Spiralgin to the reported results of some other NSAIDs, meaning that comparative evidence is lacking in some areas of the research landscape. Furthermore, the sample sizes were modest in some reviews, and long-term effects are not fully established.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Spiralgin (FAQ)

Q: How quickly does Spiralgin usually start to work?

Studies indicate that after taking Spiralgin, the active ingredient is rapidly absorbed. The concentration of the drug in the bloodstream typically reaches its highest point, known as peak plasma level, between two and four hours after the dose.

Q: How long does the effect of a single dose of Spiralgin last?

The official product information describes the elimination half-life of mefenamic acid as approximately two hours. The half-life refers to the time it takes for the concentration of the medicine in the blood to be reduced by half. This half-life is a pharmacokinetic property that defines the drug's short duration of systemic activity.

Q: Is Spiralgin available over the counter, or is it prescription-only?

According to regulatory classification, Mefenamic Acid (Spiralgin) is designated as a prescription-only medicine. It is not available for purchase without a prescription from a licensed healthcare provider.

Q: Are there certain supplements or vitamins that should be avoided with Spiralgin?

Official documents detail that Spiralgin's interaction profile involves substances that affect blood clotting (anticoagulation). For this reason, regulatory authorities note the importance of reviewing all medicines, supplements, and vitamins with a healthcare provider.

Q: Has Spiralgin been studied for uses outside of its main approved purpose?

The officially approved uses for Spiralgin are the relief of acute pain and the treatment of primary dysmenorrhea. While regulatory references primarily focus on approved indications, some sources describe the drug's use in other contexts that fall outside of the officially approved claims.

Q: Can I crush or chew Spiralgin tablets if they are hard to swallow?

Mefenamic Acid is provided as either a tablet or a capsule. Official references pertaining to these dosage forms do not describe instructions for crushing or chewing them. Alternative licensed formulations may be available for individuals who have difficulty swallowing.

Q: What is the typical timeframe for seeing the full benefits of Spiralgin?

The medicine is intended for short-term use for specific conditions. Official product information describes that the duration of therapy for acute pain is typically limited to seven days, and for menstrual pain, it is limited to two or three days. Effectiveness is monitored over these defined, short durations.

Q: Is it normal if Spiralgin makes me feel drowsy?

Regulatory safety information lists somnolence, which is the medical term for drowsiness, as a reported side effect of mefenamic acid. This effect is documented alongside other nervous system symptoms, such as headache and dizziness.

Q: What should I do if I suspect an allergic reaction to Spiralgin?

Patient counseling information advises that if signs of hypersensitivity develop, such as a rash, fever, or itching, regulatory documents indicate that discontinuation of the drug is required. For severe reactions, official patient counseling information highlights the importance of promptly seeking medical attention.

Q: What does the patient leaflet say about overdose symptoms for Spiralgin?

Regulatory documents indicate that the main feature reported in cases of acute overdose is convulsions (seizures). Other documented effects may include agitation, diarrhea, and vomiting. A potential for acute renal (kidney) failure is also noted in rare instances.

Q: Does the effect of Spiralgin wear off suddenly or gradually?

Mefenamic acid is cleared from the body gradually, as reflected by its elimination half-life of approximately two hours. This pharmacokinetic profile suggests that the drug's effect tapers off as the concentration in the bloodstream slowly decreases over a few hours.

Q: Is Spiralgin associated with changes in sleep patterns?

Regulatory documents classify Mefenamic Acid as a Nonsteroidal Anti-inflammatory Drug (NSAID). Sleep pattern disturbance is an adverse event sometimes noted in association with this class of medication, alongside other effects on the nervous system like dizziness and drowsiness.

Q: What is the primary way Spiralgin is cleared from the body?

The body breaks down mefenamic acid primarily through a metabolic process involving the enzyme CYP2C9. The final elimination of the drug’s inactive metabolites occurs through both the kidneys (renal excretion) and the liver (hepatic excretion).

Q: Are generic versions of Spiralgin available?

The active ingredient in Spiralgin, mefenamic acid, has been approved by regulatory bodies for use in generic drug products. Therefore, lower-cost generic forms are generally available.

Q: Do studies suggest any potential for misuse with Spiralgin?

While the drug is not classified as a controlled substance, published literature has described non-medical or extra-medical use of NSAIDs within this class. Official literature suggests that such use may be associated with various adverse events.

How should Spiralgin be stored and disposed of?

How to Store and Dispose of Spiralgin (Mefenamic Acid)

Official regulatory documents define strict conditions for the storage and disposal of this medication to maintain stability and ensure safety.

Storage Conditions

Requirement	Specification
Temperature	Store at Controlled Room Temperature, 20^circC to 25^circC (68^circF to 77^circF).
Protection	Keep protected from light and moisture.
Container	Must be kept in a tight, light-resistant container.
Child Safety	Mandatory instruction is to keep the medicine out of the sight and reach of children.

Disposal Instructions

Disposal must follow local regulations for unused or expired medicines. The product is not recommended for flushing down the toilet or sink. The preferred method for discarding is utilizing a community-based drug take-back program. If no program is available, the product may be mixed with an undesirable substance and placed in a sealed container for household trash disposal.

Spiralgin